Skip to main content
Contact Us
Subscribe
E-Edition
61°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
16.78
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
November 16, 2022
Via
AB Newswire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions
August 05, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Upgrades
Via
Benzinga
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
October 31, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 20, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
October 04, 2022
From
Acadia Pharmaceuticals
Via
Business Wire
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Via
Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
September 12, 2022
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory...
Via
Benzinga
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
September 12, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
August 29, 2022
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of...
Via
Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
August 09, 2022
Via
Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
August 09, 2022
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.
Via
Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
August 09, 2022
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...
Via
Benzinga
ACADIA Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
August 08, 2022
Via
Benzinga
8 Analysts Have This to Say About ACADIA Pharmaceuticals
August 05, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5
August 05, 2022
CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report
Via
Benzinga
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
August 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
August 05, 2022
Upgrades
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.